首页|微针经皮递送生物大分子药物的研究进展

微针经皮递送生物大分子药物的研究进展

扫码查看
生物大分子药物已被公认为是21世纪药物研发中最具发展前景的领域,但其递药方式单一,难以满足临床的治疗需求.微针作为新型经皮给药系统,能直接穿透角质层,将药物递送到皮肤组织进行吸收,具有无痛给药、高效递药和安全性高等优势.近年来,微针经皮递送蛋白质、多肽、核酸和疫苗等生物大分子药物的研究日益增多,在理论和技术方面均取得了重大进展.综述总结了微针递送生物大分子药物在传染病、糖尿病和肿瘤等重大疾病治疗中的应用,剖析了其在实际应用和临床转化过程中所面临的技术瓶颈,最后对微针技术的未来发展进行了展望,以期能为微针递送生物大分子药物的研发和临床转化提供参考.
Advances in Microneedle-Mediated Transdermal Delivery of Biomacromolecular Drugs
Biomacromolecular drugs have been recognized as the most promising field of drug research and development in the 21st century;however,their mode of delivery is too simple,making it difficult to meet the clinical therapeutic requirements.As a novel transdermal drug delivery system,microneedles can directly penetrate the stratum corneum and deliver drugs to the skin tissues for absorption,with the advantages of painlessness,high efficiency and high safety in delivery.In recent years,more and more studies have been conducted on the microneedle-mediated transdermal delivery of biomacromolecular drugs such as proteins,peptides,nucleic acids,and vaccines,and great progress has been made in theory and technology.This review summarizes the application of biomacromolecular drugs delivered by microneedles in the treatment of such major threats as infectious diseases,diabetes and tumor,and analyzes the technological bottlenecks involved in their practical application and clinical translation,with an outlook on the future development of microneedle technology,in the hope of providing some insight for the development and clinical translation of microneedle-mediated delivery of biomacromolecular drugs.

microneedlebiomacromolecular drugtherapeutic applicationtechnological bottleneckclinical translation

武文涛、周纯娴、吴传斌、潘昕、彭婷婷

展开 >

中山大学药学院,广东广州 510006

暨南大学药学院,广东广州 511443

微针 生物大分子药物 治疗应用 技术瓶颈 临床转化

国家自然科学基金国家自然科学基金国家自然科学基金广东省中医药局科研项目广东省自然科学杰出青年项目

821040718233011282373803202310842022B15 15020085

2024

药学进展
中国药科大学

药学进展

影响因子:0.624
ISSN:1001-5094
年,卷(期):2024.48(4)
  • 64